Research Appraisaldiagnostic

Stacking Ensemble Machine Learning for Cardiac Safety Assessment Using hiPSC-CM MEA Data

Annals of biomedical engineeringPramudito, Muhammad Adnan, Fuadah, Yunendah Nur, Kim, Yoo Seok et al.1 May 2026DOI

Clinical Snapshot

40CEBM
Evidence: Weakdiagnostic

PICO Framework

P — Population16 CiPA reference compounds tested on human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM)
I — InterventionStacking ensemble machine learning model using MEA-derived electrophysiological predictors (ΔFPDc measurements)
C — ComparatorSingle classifier models (random forest, XGBoost, artificial neural network)
O — OutcomesTorsades de Pointes (TdP) risk prediction accuracy measured by AUC, likelihood ratios, pairwise accuracy, and classification error

Bottom Line

This study reports perfect discrimination (AUC=1.000) for a machine learning ensemble predicting Torsades de Pointes risk from cardiac cell electrophysiology data. However, the results should be interpreted cautiously due to the very small validation set (16 compounds) and lack of confidence intervals, which raises concerns about overfitting. While ensemble methods theoretically improve robustness over single classifiers, the perfect performance reported here is unrealistic for practical applications. The approach shows promise for early drug screening but requires validation on larger, more diverse compound libraries before clinical implementation. The methodology lacks sufficient detail for replication, and external validation is essential. For Australian pharmaceutical companies, this represents an interesting proof-of-concept for cardiac safety assessment but shouldn't replace established regulatory testing requirements until more robust validation is demonstrated.

Evidence: Weak

Key Findings

  • P Value: Not reported

  • Effect Size: Perfect discrimination: AUC = 1.000 for stacking ensemble

  • Primary Outcome: TdP risk prediction accuracy using stacking ensemble vs single classifiers

  • Nnt Or Sensitivity: Pairwise accuracy = 1.000, classification error <0.125

  • Confidence Interval: Not reported

Clinical Application

Requires specialised MEA equipment and hiPSC-CM culture facilities, limiting accessibility to research institutions Relevant to TGA drug approval processes and pharmaceutical R&D in Australia. Could support ICH S7B/E14 cardiac safety requirements Pharmaceutical companies conducting early-stage cardiac safety screening of drug candidates

Abstract

PURPOSE: Prediction of Torsades de Pointes (TdP) risk using hiPSC-CM assays remains challenging, as many models fail to capture nonlinear patterns and exhibit unstable performance across different drugs. We examined whether a stacking ensemble can improve robustness when only two simple Δ F P D c -derived predictors are available. METHODS: Two electrophysiological predictors were derived from MEA-based FPDc measurements: the maximum change ( Δ F P D c ) and the interpolated Δ F P D c at Cmax. These features were used to train a stacking model comprising random forest (RF), XGB, and a shallow artificial neural network (ANN). Performance was assessed on 16 unseen CiPA reference compounds using AUC, likelihood ratios, pairwise accuracy, and classification error. Class weighting addressed class imbalance, and likelihood-based metrics assessed diagnostic consistency. RESULTS: The stacking ensemble consistently outperformed all single classifiers. The XGB-based meta-classifier achieved perfect discrimination for both AUC1 and AUC2 (1.000), with pairwise accuracy reaching 1.000 and classification error remaining below 0.125 across repeated evaluations. CONCLUSIONS: Combining a simple MEA-derived feature set with a stacking architecture provides a more reliable framework for early TdP risk assessment than single-model approaches. External validation using additional MEA datasets and the integration of interpretable modeling strategies will be important for future translational use.

Share:XLinkedIn

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service